You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-TNFRSF10B (TNFRSF10B) Antibodies

Full name:
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10b Antibodies (TNFRSF10B)
On are 374 Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Antibodies from 35 different suppliers available. Additionally we are shipping TNFRSF10B Proteins (43) and TNFRSF10B Kits (10) and many more products for this protein. A total of 447 TNFRSF10B products are currently listed.
list all antibodies Gene Name GeneID UniProt
TNFRSF10B 364420  
TNFRSF10B 8795 O14763
TNFRSF10B 21933 Q9QZM4

Show all species

Show all synonyms

Most Popular Reactivities for anti-TNFRSF10B (TNFRSF10B) Antibodies

Select your species and application

anti-Rat (Rattus) TNFRSF10B Antibodies:

anti-Human TNFRSF10B Antibodies:

anti-Mouse (Murine) TNFRSF10B Antibodies:

All available anti-TNFRSF10B Antibodies

Go to our pre-filtered search.

Top referenced anti-TNFRSF10B Antibodies

  1. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN4898055 : Peppa, Gill, Reynolds, Easom, Pallett, Schurich, Micco, Nebbia, Singh, Adams, Kennedy, Maini: Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. in The Journal of experimental medicine 2013 (PubMed)
    Show all 13 references for ABIN4898055

  2. Human Monoclonal TNFRSF10B Primary Antibody for Func - ABIN1106164 : Chen, Chou, Chang, Chen: Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. in Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)
    Show all 2 references for ABIN1106164

  3. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN1106166 : Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006 (PubMed)
    Show all 2 references for ABIN1106166

  4. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN238400 : Corallini, Milani, Nicolin, Secchiero: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. in Leukemia & lymphoma 2006 (PubMed)

  5. Human Polyclonal TNFRSF10B Primary Antibody for WB - ABIN222914 : Erster, Mihara, Kim, Petrenko, Moll: In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. in Molecular and cellular biology 2004 (PubMed)

  6. Human Polyclonal TNFRSF10B Primary Antibody for WB - ABIN2792103 : Baritaki, Suzuki, Umezawa, Spandidos, Berenson, Daniels, Penichet, Jazirehi, Palladino, Bonavida: Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. in Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)

More Antibodies against TNFRSF10B Interaction Partners

Human Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) interaction partners

  1. we found that CQ decreased the expression of Cbl (show CBL Antibodies), an E3 ligase of DR5, and knock-down of Cbl (show CBL Antibodies) markedly enhanced DR5 up-regulation. Other lysosomal inhibitors, including monensin and nigericin, also up-regulated DR5 and sensitized TRAIL-mediated apoptosis

  2. MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway.

  3. Edelfosine also activated p38MAPK (MAPK14 (show MAPK14 Antibodies)), and edelfosine-mediated rhTRAIL sensitization was partially regulated by a p38 (show CRK Antibodies)-mediated decrease in mitochondrial membrane potential. This study suggests a novel therapeutic strategy targeting gastric cancer cells by using the combination of edelfosine and TRAIL.

  4. Pro-survival effects by NF-kappaB (show NFKB1 Antibodies), Akt (show AKT1 Antibodies) and ERK(1 (show MAPK3 Antibodies)/2) and anti-apoptosis actions by Six1 (show SIX1 Antibodies) disrupt apoptotic functions of TRAIL-Dr4 (show HLADRB4 Antibodies)/5 pathway in ovarian cancer, which may explain why up-regulated DR4 (show HLADRB4 Antibodies) and DR5 in ovarian cancer are associated with poor prognosis and low survival ratio of the patients.

  5. CAPE/TRAIL stimulated apoptosis through the binding of TRAIL to DR5. Moreover, expression of transcription factor C/EBP homologous protein (CHOP (show DDIT3 Antibodies)) markedly increased in response to CAPE and transient knockdown of CHOP (show DDIT3 Antibodies) abolished CAPE/TRAIL-mediated apoptosis.

  6. Decreased level of placental TRAIl-R2 and previous C-section were found to be significantly correlated to placenta accreta.

  7. Structural analysis for the roles of DR5 death domain mutations on oligomerization of DR5 death domain-FADD complex in the death-inducing signaling complex formation has been presented.

  8. Results show that calmodulin (CaM (show CALM1 Antibodies)) directly binds to death receptor-5 (DR5) in a calcium dependent manner in breast cancer cells.

  9. Bee venom inhibits colon cancer cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 (show HLADRB4 Antibodies) and DR5 and inhibition of NF-kappaB (show NFKB1 Antibodies) activity.

  10. study involving a relatively large sample size showed that TNFRSF10 eQTL (show EQTN Antibodies) SNPs within lncRNAs might influence both hepatocellular carcinoma development and HBV infection

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) interaction partners

  1. Authors demonstrate, for the first time, expression of TNF-related apoptosis-inducing ligand (TRAIL (show TNFSF10 Antibodies)) and its signaling death receptor 5 (DR5) in the murine inner ear.

  2. Malignant transformation in the endometrium is related to reduction of membrane DR4 (show HLADRB4 Antibodies) and DR5 expression.

  3. TRAIL expression by osteoclast-like cells is increased in the presence of RANKL (show TNFSF11 Antibodies) and after scraping; DcR2 (show TNFRSF10D Antibodies) expression peaks at 24 hours, and and decreases at 5 days; DR5 expression peaks at 5 days

  4. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34 (show CD34 Antibodies)(+) cells.

  5. TRAIL-DR5 interaction promoted malignant behaviors of B16F10 cells.

  6. results suggest that the transmembrane domains together with their adjacent stalk regions can play a major role in control of death receptor activation thereby contributing to cell type specific differences in TRAILR1 and TRAILR2 signaling

  7. DR5 is selectively expressed by neuroprogenitor cells and newborn neurons.

  8. Results suggest that excessive iodine could induce TRAIL and DR5 abnormal expression in thyroid. TRAIL band with DR5 to promote follicular cells apoptosis thus mediate thyroid destruction in EAT.

  9. NK cells inhibit dendritic cell cross-priming, but not direct priming, in a TRAIL/DR5-dependent manner.

  10. Antibody-based therapy targeting DR5 is an efficient strategy not only to eliminate TRAIL-sensitive tumor cells.

TNFRSF10B Antigen Profile

Antigen Summary

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene.

Alternative names and synonyms associated with TNFRSF10B

  • tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b) antibody
  • tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) antibody
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b-b) antibody
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b) antibody
  • CD262 antibody
  • DR5 antibody
  • KILLER antibody
  • KILLER/DR5 antibody
  • Ly98 antibody
  • MK antibody
  • TNFRSF10B antibody
  • TRAIL-R2 antibody
  • TRAILR2 antibody
  • TRICK2 antibody
  • TRICK2A antibody
  • TRICK2B antibody
  • TRICKB antibody
  • xDR-M1 antibody
  • xDR-M2 antibody
  • ZTNFR9 antibody

Protein level used designations for TNFRSF10B

tumor necrosis factor receptor superfamily, member 10b , death receptor-M2 , death receptor-M1 , Fas-like protein , TNF-related apoptosis-inducing ligand receptor 2 , apoptosis inducing protein TRICK2A/2B , apoptosis inducing receptor TRAIL-R2 , cytotoxic TRAIL receptor-2 , death domain containing receptor for TRAIL/Apo-2L , death receptor 5 , p53-regulated DNA damage-inducible cell death receptor(killer) , tumor necrosis factor receptor superfamily member 10B , tumor necrosis factor receptor-like protein ZTNFR9 , KILLER/DR5 TRAIL death-inducing receptor

364420 Rattus norvegicus
282533 Bos taurus
404687 Xenopus laevis
404688 Xenopus laevis
448240 Xenopus (Silurana) tropicalis
742898 Pan troglodytes
8795 Homo sapiens
21933 Mus musculus
Selected quality suppliers for anti-TNFRSF10B (TNFRSF10B) Antibodies
Did you look for something else?